Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth

Cancer Research

Volumn 60, Issue 8, 2000, Pages 2190-2196

  Yokoyama, Yumi ^a   Dhanabal, Mohanraj ^c   Griffioen, Arjan W ^d   Sukhatme, Vikas P ^c   Ramakrishnan, S ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Center for Immunology   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ENDOSTATIN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

ANGIOSTATINS; ANIMALS; APOPTOSIS; CELL DIVISION; CHICK EMBRYO; CHORION; COLLAGEN; DRUG SYNERGISM; ENDOSTATINS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASM, RESIDUAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PICHIA; PLASMINOGEN; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0034655135     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
2. Kandel, J., Bossy-Wetzel, E., Radvanyi, F., Klagsbrun, M., Folkman, J., and Hanahan, D. Neovascularization is associated with a switch to the export of bFGF in the multislep development of fibrosarcoma. Cell, 66: 1095-1104, 1991.
3. Ferrara, N., Houck, K., Jakeman, L., and Leung, D. W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev., 13: 18-32, 1992.
4. Maisonpierre, P. C., Suri, C., Jones, P. F., Bartunkova, S., Wiegand, S. J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T. H., Papadopoulos, N., Daly, T. J., Davis, S., Sato, T. N., and Yancopoulos, G. D. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (Washington DC), 277: 55-60, 1997.
5. Goede, V., Schmidt, T., Kimmina, S., Kozian, D., and Augustin, H. G. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab. Investig., 78: 1385-1394, 1998.
6. Greene, M. H., Clark, J. W., and Blayney, D. W. The epidemiology of ovarian cancer. Semin. Oncol., 11: 209-226, 1984.
7. Rossing, M. A., Daling, J. R., Weiss, N. S., Moore, D. E., and Self, S. G. Ovarian tumors in a cohort of infertile women. N. Engl. J. Med., 331: 771-776, 1994.
8. Auersperg, N., Edelson, M. I., Mok, S. C. Johnson, S. W., and Hamilton, T. C. The biology of ovarian cancer. Semin. Oncol., 25: 281-304, 1998.
9. Berchuck, A., Elbendary, A., Havrilesky, L., Rodriguez, G. C., and Bast, R. C., Jr. Pathogenesis of ovarian cancers. J. Soc. Gynecol. Investig., 1: 181-190, 1994.
10. Olson, T. A., Mohanraj, D., Carson, L. F., and Ramakrishnan, S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res., 54: 276-280, 1994.
11. Yoneda, J., Kuniyasu, H., Crispens, M. A., Price, J. E., Bucana, C. D., and Fidler, I. J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice, J. Natl. Cancer Inst., 90: 447-454, 1998.
12. Hartenbach, E. M., Olson, T. A., Goswitz, J. J., Mohanraj, D., Twiggs, L. B., Carson, L. F., and Ramakrishnan, S. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett., 121: 169-175, 1997.
13. Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., and Ramakrishnan, S. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer (Phila.), 80: 98-106, 1997.
14. Olson, T. A., Mohanraj, D., Roy, S., and Ramakrishnan, S. Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int. J. Cancer, 73: 865-870, 1997.
15. Nagy, J. A., Morgan, E. S., Herzberg, K. T., Manseau, E. J., Dvorak, A. M., and Dvorak, H. F. Pathogenesis of asciles tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res., 55: 376-385, 1995.
16. Simpson-Herren, L., Sanford, A. H., and Holmquist, J. P. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat. Rep., 60: 1749-1760, 1976.
17. Luesley, D. M., Chan, K. K., Lawton, F. G., Blackledge, G. R., and Mould, J. M. Survival after negative second-look laparotomy. Eur. J. Surg. Oncol., 15: 205-210, 1989.
18. Luesley, D., Finn, C., and Varma, R. The role of surgery in epithelial ovarian cancer. In: F. Sharp, W. P. Mason, and W. Creasman (eds.), Ovarian Cancer 2, pp. 357-367. London, United Kingdom: Chapman & Hall, 1992.
19. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
20. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Cao, Y., Moses, M., Lane, W. S., Sage, E. H., and Folkman, J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harbor Symp. Quant-Biol., 59: 471-482, 1994.
21. Folkman, J. Angiogenesis inhibitors generated by tumors. Mol. Med., 1: 120-122, 1995.
22. Redlitz, A., Daum, G., and Sage, E. H. Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells. J. Vasc. Res., 36: 28-34, 1999.
23. Sim, B. K., O'Reilly, M. S., Liang, H., Fortier, A. H., He, W., Madsen, J. W., Lapcevich, R., and Nacy, C. A. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res., 57: 1329-1334, 1997.
24. Wu, Z., O'Reilly, M.S., Folkman, J., and Shing, Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem. Biophys. Res. Commun., 236: 651-654, 1997.
25. Gorski, D. H., Mauceri, H. J., Salloum, R. M., Gately, S., Hellman, S., Beckett, M. A., Sukhatme, V. P., Soff, G. A., Kufe, D. W., and Weichselbaum, R. R. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res., 58: 5686-5689, 1998.
26. Lannutti, B. J., Gately, S. T., Quevedo, M. E., Soff, G. A., and Paller, A. S. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res., 57: 5277-5280, 1997.
27. Kirsch, M., Strasser, J., Allende, R., Bello, L. Zhang, J., and Black, P. M. Angiostatin suppresses malignant glioma growth in vivo. Cancer Res., 58: 4654-4659, 1998.
28. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead. J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
29. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.
30. Dhanabal, M., Ramchandran, R., Volk, R., Stillman, I. E., Lombardo. M., Iruela-Arispe, M. L., Simons, M., and Sukhatme, V. P. Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res., 59: 189-197, 1999.
31. Volpert, O. V., Fong, T., Koch, A. E., Peterson, J. D., Waltenbaugh, C., Tepper, R. I., and Bouck, N. P. Inhibition of angiogenesis by interleukin 4. J. Exp. Med., 188: 1039-1046, 1998.
32. Dawson, D. W., Volpert, O. V., Gillis, P., Crawford, S. E., Xu, H., Benedict, W., and Bouck, N. P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science (Washington DC), 285: 245-248, 1999.
33. O'Reilly, M. S., Pirie-Shepherd, S., Lane, W. S., and Folkman, J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science (Washington DC), 285: 1926-1928, 1999.
34. Ramakrishnan, S., Olson, T. A., Bautch, V. L., and Mohanraj, D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res., 56: 1324-1330, 1996.
35. Mohanraj, D., Olson, T., and Ramakrishnan, S. Expression of biologically active human vascular endothelial growth factor in yeast. Growth Factors, 12: 17-27, 1995.
36. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-942, 1987.
37. Yoon, S. S., Eto, H., Lin, C. M., Nakamura, H., Pawlik, T. M., Song, S. U., and Tanabe, K. K. Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res., 59: 6251-6256, 1999.
38. Olson, T. A., Mohanraj, D., and Ramakrishnan, S. In vivo neutralization of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth. Int. J. Oncol., 8: 505-511, 1996.
39. Boehm, T., O'Reilly, M. S., Keough, K., Shiloach, J., Shapiro, R., and Folkman, J. Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem. Biophys. Res. Commun., 252: 190-194, 1998.
40. Boehm, T., Pirie-Shepherd, S., Trinh, L. B., Shiloach, J., and Folkman, J. Disruption of the KEX1 gene in Pichia pastoris allows expression of full-length murine and human endostatin. Yeast, 15: 563-572, 1999.
41. Yamaguchi, N., Anand-Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., Que, I., Lowik, C., Timpl, R., and Olsen, B. R. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J., 18: 4414-4423, 1999.
42. Ji, W. R., Barrientos, L. G., Llinas, M., Gray, H., Villarreal, X., DeFord, M. E., Castellino, F. J., Kramer, R. A., and Trail, P. A. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem. Biophys. Res. Commun., 247: 414-419, 1998.
43. Lee, T. H., Rhim, T., and Kim, S. S. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells. J. Biol. Chem., 273: 28805-28812, 1998.
44. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
45. Chang, Z., Choon, A., and Friedl, A. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Am. J. Pathol., 155: 71-76, 1999.
46. Moser, T. L., Stack, M. S., Asplin, I., Enghild, J. J., Hojrup, P., Everitt, L., Hubchak, S., Schnaper, H. W., and Pizzo, S. V. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. USA, 96: 2811-2816, 1999.
47. Dhanabal, M., Ramchandran, R., Waterman, M. J., Lu, H., Knebelmann, B., Segal, M., and Sukhatme, V. P. Endostatin induces endothelial cell apoptosis. J. Biol. Chem., 274: 11721-11726, 1999.
48. Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M. J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., Soff, G. A., Sukhatme, V. P., Kufe, D. W., and Weichselbaum, R. R. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.), 394: 287-291, 1998.
49. Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M. Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., and Weichselbaum, R. R. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res., 59: 3374-3378, 1999.